Dr. Perez-Soler Discusses Treatment Options for NSCLC
Roman Perez-Soler, MD, Chairman, Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine of Yeshiva University, talks about the advances in treatment options for non-small cell lung cancer (NSCLC). Perez-Soler states that targeted agents represent the most dramatic changes in the treatment of NSCLC. New agents are available that target subgroups with molecular alterations in EGFR and ALK. These alterations are driver mutations in tumor cells and as a result render high response rates. Despite the initial response to a medication most tumors will eventually develop resistance. The next step for research is to understand how these tumors develop these resistance mechanisms.
Video Rating: 0 / 5
JVZoo Product Feed
Dr. Scagliotti Discusses EGFR Mutations in NSCLC
Giorgio V. Scagliotti, MD, PhD, head of the Thoracic Oncology Unit, Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Orbassano, Italy, explains that the identification of epidermal growth factor receptor (EGFR) mutations in the subset of non-small cell lung cancer (NSCLC) has greatly changed the survival expectations in stage IV NSCLC. Scagliotti discusses the benefit patients receive simply by taking one pill a day, gefitinib or erlotinib, both tyrosine kinase inhibitors. This benefit has been established using multiple trials that looked at several demographic factors. These trials have showed an increase in the progression free survival of patients receiving EGFR-TKIs.
Video Rating: 0 / 5
JVZoo Product Feed
GRACEcast-025_Lung-Cancer_Questions and Trials for NSCLC
cancergrace.org This slide presentation by Dr. Heather Wakelee, medical oncologist at Stanford University, describes the key clinical research issues being addressed in post-operative treatment of resected non-small cell lung cancer (NSCLC).
Video Rating: 0 / 5
JVZoo Product Feed
Categories: Videos Tags: gracecast025_lungcancer_questions, nsclc, trials
GRACEcast-027_Lung-Cancer_The Role of Surgery in NSCLC Management
cancergrace.org This slide presentation by Dr. Ralph Aye, thoracic surgeon and Chief of the Thoracic Oncology Division at Swedish Cancer Institute in Seattle, provides a general introduction to surgical management options for early stage non-small cell lung cancer.
Video Rating: 5 / 5
JVZoo Product Feed
Categories: Videos Tags: gracecast027_lungcancer_the, nsclc, management, role, surgery
GRACEcast-074_Lung-Cancer_CCILC – Adjuvant Therapy for Smaller Node-Negative NSCLC
cancergrace.org Case-based discussion with multiple lung cancer experts on whether to recommend post-operative (adjuvant) chemotherapy for a patient with a 4+ cm non-small cell lung cancer (NSCLC) tumor with some high risk features.
Video Rating: 0 / 5
JVZoo Product Feed
Categories: Videos Tags: nodenegative, adjuvant, nsclc, gracecast074_lungcancer_ccilc, smaller, therapy
GRACEcast-057_Lung-Cancer_Expert Round Table – Optimal NSCLC Treatment for Elderly / Frail
cancergrace.org Case discussion with Drs. Paul Hesketh of the Lahey Clinic and Karen Kelly of Kansas University Medical Center, covering question of optimal treatment for patients with advanced NSCLC who are elderly or have a marginal performance status.
Video Rating: 0 / 5
JVZoo Product Feed
Categories: Videos Tags: optimal, round, elderly, frail, nsclc, gracecast057_lungcancer_expert, treatment, table
Dr. Belani Discusses Driver Mutations in NSCLC
Chandra P. Belani, MD, Deputy Director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey Medical Center & College of Medicine, discusses the multicenter Lung Cancer Mutation Consortium (LCMC) study that sought to detect driver mutations in patients with non-small cell lung cancer (NSCLC). The detection of various driver mutations could help compartmentalize overall NSCLC. Determining the exact mutation responsible for tumor growth could help identify the patients that are eligible to receive specific targeted agents. The LCMC study found that approximately 54% of patients with NSCLC have some form of a mutation. The major abnormalities include mutations in KRAS, EGFR, c-Met, PI3K, and the EML4-ALK rearrangement. Most of these alterations appear to be mutually exclusive; very few tumors have dual or triple abnormalities. According to Belani this research only scratches the surface of the NSCLC biology. Subsequent discoveries will show that NSCLC is heterogeneous; further aberrations will be discovered as more research is completed.
JVZoo Product Feed
Part 2: SOX2 Analysis in NSCLC
In this talk, a study on SOX2 amplification in non-small cell lung cancer with a special focus on IHC assessment using the Definiens Tissue Studio image analysis software will be presented. The aim of the study was to verify SOX2 amplification and protein over-expression in non-small cell lung cancers (NSCLC) and to compare these results with patient and tumor characteristics. A total of 940 NSCLCs from two independent population-based cohorts containing predominantly adenocarcinomas of the lung and squamous cell lung carcinomas, were assessed by fluorescence in-situ hybridization (FISH) and immunohistochemistry (IHC) to study SOX2 amplification and expression level. For protein expression analysis, the expression level was explored by utilizing Definiens Tissue Studio.
Video Rating: 0 / 5
JVZoo Product Feed
P1.255 Fitness of RECIST 1.1 for non-small cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhi1140?
Warning: mysql_fetch_array(): supplied argument is not a valid MySQL result resource in /home/joker584/public_html/guide-to-mesothelioma.com/wp-content/plugins/jvzoo-ad-manager-v1/jvzoo-ad-manager.php on line 346
Question by ib 11 sharapova maria molai: P1.255 Fitness of RECIST 1.1 for non-small cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhi1140?
Best answer:
Answer by Edwin Kimberly
http://answers.yahoo.com/question/index;_ylt=Akz5tv_cJVzB.pZhmPSIkLXsy6IX;_ylv=3?qid=20090724231210AASBbRL
Add your own answer in the comments!
JVZoo Product Feed
Categories: News Tags: tyrosine, egfr, cancer, p1.255, nsclc, nonsmall, fitness, cell, inhi1140, lung
ASCO 2009: Maintenance therapy for NSCLC
Dr. Vincent A. Miller – MD Memorial Sloan-Kettering Cancer Center, New York, USA ASCO press conference: A phase III trial finds that adding erlotinib (Tarceva) to bevacizumab-based (Avastin) maintenance therapy in patients with advanced NSCLC delays cancer progression more than maintenance treatment with bevacizumab alone.
cancergrace.org Lecture on history and general approaches for radiation, with specific attention to its role in post-operative treatment of head/neck cancer, by Dr. Alex Lin, Assistant Professor of Radiation Oncology at the Univ. of Pennsylvania.
Video Rating: 0 / 5
JVZoo Product Feed
anybody know anything about NSCLC (non small cell lung cancer)?
Question by shnaz: anybody know anything about NSCLC (non small cell lung cancer)?
please lend me any information u have about this my mom has it and is in the final stage, i wanted to see if i could get any useful information
any information u havee would be great, survival rates, sideeffects of chemo and radiation, anythingg
Best answer:
Answer by notalonewithcancer
What all would you like to know. I have stage iv NSCLC… if you would like to email me, feel free to do so.
Survival rate varies from person to person, it really depends on the state of health at the time of diagnosis. For me, I was dx’d on May 15th,06.. my onc at that time told me I only had 2-4 months without treatment, but with chemo I may have a year. I decided to take the treatments to give myself time to try to ‘fix me’. I worked very hard on nutritional choices in my diet, changed my lifestyle to concentrate on healing.. and here I am still alive nearly 3 years later. The chemo they gave me for my first 6 rounds kept me stable but did nothing to reduce my cancer, actually my primary had a couple more babies as I went thru chemo. After my 6 rounds I had 9 months off to recoup from the treatment. During this time I remained as active as I could be, ate a very healthy diet and rested as well as I could. Unfortunately I developed osteo from the chemo treatment so am dealing with that pain. So with whatever treatment your mom gets, be sure to check to see if bone loss can occur and ask the onc what can be done to prevent that from happening to her. After my 9 months off, I went for another 6 rounds of chemo, finished in January of this year, tolerated it well and now I am on a watch and wait til the end of April. I am not sure what else to tell you, only that your mom is in for the fight of her life, she should eat as nutritionally as she can to keep her body in top shape, exercise moderately, rest when she needs to, any supplements she wants to take should be cleared by her onc if she is to be going thru chemo. STAY POSITIVE.. sorry for the caps but staying positive is a must. The mind and body work closely together.. “What the mind can conceive, the body can achieve”. Please email if you ever need to talk. With my treatments, my diet and lifestyle change and keeping a positive attitude, my cancer has not advanced outside of the original site.. so I just keep doing what I am doing, and hopefully can keep adding on a year of life, one year at a time.
I didn’t have radiation so can’t comment on the side effects of that. But for the chemo, my worst times would be the third day after chemo infusion, my largest bones, ie: thighs, arm bones, would get very sore, also my muscles would ache with flu like symptoms. This is not really a bad thing, as it means the good cells are rebuilding. I really didn’t have bad side effects, some fatigue and of course hair loss, but that was about it.
What do you think? Answer below!
JVZoo Product Feed
GRACEcast-067_Lung-Cancer_Expert Round Table – NSCLC Molecular Markers Case 3
cancergrace.org Case discussion with Drs. Tom Hensing of in Chicago & David Jackman in Boston, discussing practical issues around molecular marker testing & recommended treatments for first line & maintenance therapy for a never-smoker with a lung adenocarcinoma.
Video Rating: 5 / 5
JVZoo Product Feed
Categories: Videos Tags: molecular, case, gracecast067_lungcancer_expert, nsclc, markers, table, round
Anyone know the optimal duration of chemotherapy for stage 4 NSCLC?
Question by wildchild: Anyone know the optimal duration of chemotherapy for stage 4 NSCLC?
My mother-in-law has stage 4 NSCLC (non small cell lung cancer) it has metastized to her brain and her bones. My question is how long should chemotherapy be given to her?
Best answer:
Answer by m _s6184@yahoo.com
m_s6184@yahoo.com
What do you think? Answer below!
JVZoo Product Feed
GRACEcast-024_Lung-Cancer_Cancer Lifeline Lecture Pt3 Adv. NSCLC
cancergrace.org This slide presentation is part of a lecture by medical oncologist and lung cancer expert Dr. Jack West, in which he covers the optimal treatment strategies for locally advanced (stage III), unresectable NSCLC.
Video Rating: 0 / 5
JVZoo Product Feed
GRACEcast-065_Lung-Cancer_Expert Round Table – NSCLC Molecular Markers
cancergrace.org Case discussion with Drs. Tom Hensing of in Chicago & David Jackman in Boston, discussing practical issues around molecular marker testing & recommended treatments for first line & maintenance therapy for a patient with advanced squamous cell NSCLC.
cancergrace.org Case discussion with Drs. Paul Hesketh of the Lahey Clinic and Karen Kelly of Kansas University Medical Center, discussing current evidence and challenges of post-operative treatments for early stage NSCLC in elderly and/or frail patients.
Video Rating: 0 / 5
JVZoo Product Feed
Jean’s CyberKnife Treatment – NSCLC Non Small Cell Lung Cancer_final.wmv
Jean was 92 years old at the time of her CyberKnife lung cancer treatment and was not eligible for surgery. Jean did great and we interviewed her then and followed up with her a year later and she had no evidence of the disease. Al, her husband of 72 years, is extremely grateful and to have this quality time with his lovely bride. Here is their CyberKnife story…
Video Rating: 0 / 5
JVZoo Product Feed
Categories: Videos Tags: lung, nsclc, cancer_final.wmv, cell, jeans, cyberknife, treatment, small
ASCO 2009: Oestrogen and progestin therapy increases NSCLC risk
ASCO 2009: Rowan T. Chlebowski, MD, PhD – Harbor-UCLA Medical Center – Los Angeles: Menopausal Hormone Therapy with Estrogen and Progestin Linked to Increased Risk of Death from Non-Small Cell Lung Cancer Researchers have shown that use of hormone therapy with estrogen plus progestin increases the risk of dying from non-small cell lung cancer (NSCLC) in women with the disease. Lung cancer is the leading cause of cancer death in US women.
JVZoo Product Feed
Dr. Belani Discusses NSCLC Adjuvant Therapy
Chandra P. Belani, MD, Deputy Director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey Medical Center & College of Medicine, discusses recent changes to adjuvant therapy for non-small cell lung cancer (NSCLC). Adjuvant therapy is the current standard of care for patients with resectable NSCLC. Various trials have suggested that the absolute improvement in overall survival from adjuvant treatment is 4.1-15%. Most practitioners assume an approximate 7-8% overall improvement. Recent trials have suggested that new combinations such as cisplatin and pemetrexed have an equivalent effect, and may be more feasible, than the current standard of cisplatin plus vinorelbine or etoposide, which has recently been the focus of multiple studies. While a comparison of these standards is not currently needed it has resulted in a paradigm shift in adjuvant care for early-stage resectable NSCLC, with the exception of patients with stage IA-IB that measures less than 4 cm.
Video Rating: 5 / 5
JVZoo Product Feed
GRACEcast-030_Lung-Cancer_Gadgeel on Advanced NSCLC Management
cancergrace.org This slide presentation by Dr. Shirish Gadgeel, medical oncologist at Wayne State University, discusses the considerations and evidence about whether locally advanced (Stage III) NSCLC should be managed surgically or with chemo/radiation alone.
Video Rating: 0 / 5
JVZoo Product Feed
Categories: Videos Tags: gracecast030_lungcancer_gadgeel, advanced, management, nsclc
GRACEcast-056_Lung-Cancer_Expert Round Table – Managing NSCLC for Elderly / Frail
cancergrace.org Case discussion with Drs. Paul Hesketh of the Lahey Clinic and Karen Kelly of Kansas University Medical Center, discussing options for administering multimodality therapy for stage III NSCLC in patients who are elderly or have a marginal performance status.
Video Rating: 0 / 5
JVZoo Product Feed
